These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23698222)

  • 1. Hydromorphone does not influence the immune response in patients affected by chronic pain.
    Coaccioli S; Di Cato L; Panaccione A; Crapa ME; Paladini A; Piroli A; Marinangeli F
    Clin Ter; 2013; 164(2):e97-9. PubMed ID: 23698222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
    Nalamachu SR; Kutch M; Hale ME
    J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.
    Paramanandam G; Prommer E; Schwenke DC
    J Palliat Med; 2011 Sep; 14(9):1029-33. PubMed ID: 21823925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of hydromorphone in pain killing].
    Telekes A
    Lege Artis Med; 2008 Oct; 18(10):675-9. PubMed ID: 19227610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
    Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
    J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of hydromorphone therapy on psychophysical measurements of the descending inhibitory pain systems in patients with chronic radicular pain.
    Suzan E; Treister R; Pud D; Haddad M; Eisenberg E
    Pain Med; 2015 Jan; 16(1):168-75. PubMed ID: 25219395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: is hydromorphone therapy a double-edged sword?
    Suzan E; Eisenberg E; Treister R; Haddad M; Pud D
    Pain Physician; 2013 Jan; 16(1):65-76. PubMed ID: 23340535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M; Khan A; Kutch M; Li S
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain.
    Wallace M; Thipphawong J
    Pain Med; 2010 Oct; 11(10):1477-88. PubMed ID: 21199302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New opioid preparations in the treatment of pain].
    Kalso E
    Duodecim; 1999; 115(20):2211-4. PubMed ID: 11973924
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies.
    Moulin DE; Richarz U; Wallace M; Jacobs A; Thipphawong J
    J Pain Palliat Care Pharmacother; 2010 Sep; 24(3):200-12. PubMed ID: 20718640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
    Coluzzi F; Mattia C
    Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
    Sittig HB
    MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):95-8. PubMed ID: 15662898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of OROS® hydromorphone in patients suffering from severe chronic pain: A Study undertaken in routine clinical practice.
    Stepanović A; Pirc J; Lahajnar Čavlović S
    Wien Klin Wochenschr; 2011 Sep; 123(17-18):531-5. PubMed ID: 21710117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
    Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
    J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.